Whereas a select few assays, for example, APC or KRAS mutations in colorectal cancer, BRAF in melanoma encompass a significant proportion of patients, and are thus reliable aberrations to use a surrogate for tumour fraction, the equivalent targets have yet to be demonstrated in MIBC. The gene discussed is KRAS; the disease is neoplasm.